Splash Beverage Group Expands CannEpil License to Veterinary

What Happened Splash Beverage Group, Inc. (SBEV) filed a Form 8-K on July 30, 2026 disclosing an addendum dated July 29, 2026 to its exclusive global license agreement with Argent BioPharma Limited (ASX/LSE: RGT) for CannEpil®. The Addendum expands the licensed field to include veterinary applications, updates royalty rates, and extends certain contractual deadlines. The original License Agreement was dated July 6, 2026; the Addendum is filed as Exhibit 10.1 and a related press release is furnished as Exhibit 99.1.

Key Details

• Addendum date: July 29, 2026; Form 8-K filed July 30, 2026.
• Parties: Splash Beverage Group, Inc. and Argent BioPharma Limited (ASX/LSE: RGT).
• Royalty rates: 10% of Net Revenue for veterinary applications; 15% of Net Revenue for human applications.
• The Addendum also extends various deadlines under the original July 6, 2026 License Agreement.

Why It Matters This amendment formally adds veterinary uses to the exclusive global CannEpil license, broadening the potential market for the product. The stated royalty splits (10% vet, 15% human) define how revenue from CannEpil sales will be shared with the licensor and therefore affect the portion of sales Splash would retain. Investors should watch for follow-up disclosures (development, regulatory progress, commercialization plans, and actual sales) to assess the timing and size of any revenue impact.